Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: Results of a phase 2 observational extension

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Kira, Jun ichi ^a   Itoyama, Yasuto ^b   Kikuchi, Seiji ^c   Hao, Qi ^d   Kurosawa, Takayoshi ^e   Nagato, Kazuo ^f   Tsumiyama, Isao ^e   von Rosenstiel, Philipp ^g   Zhang Auberson, Lixin ^g   Saida, Takahiko ^d,h,i  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c HOKKAIDO MEDICAL CENTER   (Japan)

^d Institute of Neurotherapeutics   (Japan)

^e NOVARTIS PHARMA K K   (Japan)

^f MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^g NOVARTIS PHARMA AG   (Switzerland)

^h Kyoto Min iren Central Hospital   (Japan)

ⁱ KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aquaporin 4; Fingolimod; Longitudinally extensive spinal cord lesions; Multiple sclerosis; Phase 2 study

Indexed keywords

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892956539     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-21     Document Type: Article

References (24)

1. US Food and Drug Administration (FDA) FDA approves first oral drug to reduce MS relapses Sep 22. 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm, US Food and Drug Administration (FDA).
2. European Medicines Agency (EMA) Assessment report Gilenya. Doc Ref: EMA/108602/2011. 17 February 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf, European Medicines Agency (EMA) Assessment report.
3. Mitsubishi Tanabe Pharma Corporation Approval for " IMUSERA® capsules 0.5mg" Japan's first once-daily oral dosing multiple sclerosis treatment (press release). http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/eMTPC110926_IMU.pdf, Mitsubishi Tanabe Pharma Corporation.
4. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897. 10.1038/nrd3248, 21031003.
5. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010, 33:91-101. 10.1097/WNF.0b013e3181cbf825, 2859693, 20061941.
6. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415. 10.1056/NEJMoa0907839, 20089954.
7. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140. 10.1056/NEJMoa052643, 16971719.
8. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401. 10.1056/NEJMoa0909494, 20089952.
9. Novartis Pharmaceuticals Corporation FDA Peripheral and CNS Advisory Committee Meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM216556.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=fingolimod, Novartis Pharmaceuticals Corporation.
10. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 2012, 18:1269-1277. 10.1177/1352458511435984, 22354739.
11. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" Ann Neurol 2005, 58:840-846. 10.1002/ana.20703, 16283615.
12. ICH harmonised tripartite guidelines for good clinical practice E6(R1) International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use, Geneva (1996). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf, ICH harmonised tripartite guidelines for good clinical practice E6(R1).
13. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html, World Medical Association.
14. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010, 16:197-207. 10.1177/1352458509357065, 20028707.
15. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010, 11:781-791. 10.2217/pgs.10.49, 2904527, 20504253.
16. Satoh T. Genetic polymorphism in drug metabolism and toxicity: Linking animal research and risk assessment in man. AATEX 2007, 14:443-445.
17. Yoshimura S, Isobe N, Yonekawa T, Matsushita T, Masaki K, Sato S, Kawano Y, Yamamoto K, Kira J. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 2012, 7:e48592. 10.1371/journal.pone.0048592, 3494689, 23152786.
18. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011, 10:520-529. 10.1016/S1474-4422(11)70099-0, 21571593.
19. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115:84-105. 10.1016/j.pharmthera.2007.04.006, 17561264.
20. Gilenya (fingolimod) Summary of Product Characteristics. Revised 10 February 2012. [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf].
21. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl 12):1-39.
22. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489. 10.1212/01.wnl.0000216139.44259.74, 16717206.
23. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, Goto J, Shimizu T, Takatsu M, Sakurai Y, et al. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75:1423-1427. 10.1212/WNL.0b013e3181f8832e, 20826711.
24. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012, 18:113-115. 10.1177/1352458511431973, 22146605.